The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability |
Lee, Yun Jeong
(Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center)
Lee, Eun-Young (Division of Translational Science, Research Institute, National Cancer Center) Choi, Bo Hee (Division of Translational Science, Research Institute, National Cancer Center) Jang, Hyonchol (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center) Myung, Jae-Kyung (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center) You, Hye Jin (Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center) |
1 | Leonetti, C., Biroccio, A., Candiloro, A., Citro, G., Fornari, C., Mottolese, M., Del Bufalo, D., and Zupi, G. (1999). Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin. Cancer Res. 5, 2588-2595. |
2 | Luengo, A., Gui, D.Y., and Vander Heiden, M.G. (2017). Targeting metabolism for cancer therapy. Cell Chem. Biol. 24, 1161-1180. DOI |
3 | Maran, R.R., Thomas, A., Roth, M., Sheng, Z., Esterly, N., Pinson, D., Gao, X., Zhang, Y., Ganapathy, V., Gonzalez, F.J., et al. (2009). Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328, 469-477. DOI |
4 | Jo, M.J., Paek, A.R., Choi, J.S., Ok, C.Y., Jeong, K.C., Lim, J.H., Kim, S.H., and You, H.J. (2015). Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment. Eur. J. Pharmacol. 769, 257-265. DOI |
5 | Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R.H.Y., Ayaz, M., Lawrence, H.R., Kennedy, P., and Sebti, S.M. (2018). GSK3 suppression upregulates beta-catenin and c-Myc to abrogate KRas-dependent tumors. Nat. Commun. 9, 5154. DOI |
6 | Klag, T., Thomas, M., Ehmann, D., Courth, L., Mailander-Sanchez, D., Weiss, T.S., Dayoub, R., Abshagen, K., Vollmar, B., Thasler, W.E., et al. (2018). Beta-defensin 1 is prominent in the liver and induced during cholestasis by bilirubin and bile acids via farnesoid X receptor and constitutive androstane receptor. Front. Immunol. 9, 1735. DOI |
7 | Kong, B., Zhu, Y., Li, G., Williams, J.A., Buckley, K., Tawfik, O., Luyendyk, J.P., and Guo, G.L. (2016). Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G295-G302. DOI |
8 | Okuyama, H., Endo, H., Akashika, T., Kato, K., and Inoue, M. (2010). Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res. 70, 10213-10223. DOI |
9 | Nagarajan, A., Malvi, P., and Wajapeyee, N. (2016). Oncogene-directed alterations in cancer cell metabolism. Trends Cancer 2, 365-377. DOI |
10 | Okita, A., Takahashi, S., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., and Ishioka, C. (2018). Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget 9, 18698-18711. DOI |
11 | Ortmayr, K., Dubuis, S., and Zampieri, M. (2019). Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat. Commun. 10, 1841. DOI |
12 | Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McCuine, S., Burge, C.B., Sharp, P.A., and Young, R.A. (2010). c-Myc regulates transcriptional pause release. Cell 141, 432-445. DOI |
13 | Sarosiek, K.A., Fraser, C., Muthalagu, N., Bhola, P.D., Chang, W., McBrayer, S.K., Cantlon, A., Fisch, S., Golomb-Mello, G., Ryan, J.A., et al. (2017). Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell 31, 142-156. DOI |
14 | Satoh, K., Yachida, S., Sugimoto, M., Oshima, M., Nakagawa, T., Akamoto, S., Tabata, S., Saitoh, K., Kato, K., Sato, S., et al. (2017). Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc. Natl. Acad. Sci. U. S. A. 114, E7697-E7706. DOI |
15 | Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683. DOI |
16 | Kuipers, E.J., Grady, W.M., Lieberman, D., Seufferlein, T., Sung, J.J., Boelens, P.G., van de Velde, C.J., and Watanabe, T. (2015). Colorectal cancer. Nat. Rev. Dis. Primers 1, 15065. DOI |
17 | Lajczak, N.K., Saint-Criq, V., O'Dwyer, A.M., Perino, A., Adorini, L., Schoonjans, K., and Keely, S.J. (2017). Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human beta-defensin-1 and -2 secretion by colonic epithelial cells. FASEB J. 31, 3848-3857. DOI |
18 | Hsieh, A.L., Walton, Z.E., Altman, B.J., Stine, Z.E., and Dang, C.V. (2015). MYC and metabolism on the path to cancer. Semin. Cell Dev. Biol. 43, 11-21. DOI |
19 | Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J.R. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514. DOI |
20 | Smith, D.R., Myint, T., and Goh, H.S. (1993). Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br. J. Cancer 68, 407-413. DOI |
21 | Stine, Z.E., Walton, Z.E., Altman, B.J., Hsieh, A.L., and Dang, C.V. (2015). MYC, metabolism, and cancer. Cancer Discov. 5, 1024-1039. DOI |
22 | Sveen, A., Bruun, J., Eide, P.W., Eilertsen, I.A., Ramirez, L., Murumagi, A., Arjama, M., Danielsen, S.A., Kryeziu, K., Elez, E., et al. (2018). Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clin. Cancer Res. 24, 794-806. DOI |
23 | Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308. DOI |
24 | Takahashi, S., Tanaka, N., Fukami, T., Xie, C., Yagai, T., Kim, D., Velenosi, T.J., Yan, T., Krausz, K.W., Levi, M., et al. (2018). Role of farnesoid X receptor and bile acids in hepatic tumor development. Hepatol. Commun. 2, 1567-1582. DOI |
25 | Dang, C.V. (2012). MYC on the path to cancer. Cell 149, 22-35. DOI |
26 | Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337. DOI |
27 | Altman, B.J., Hsieh, A.L., Sengupta, A., Krishnanaiah, S.Y., Stine, Z.E., Walton, Z.E., Gouw, A.M., Venkataraman, A., Li, B., Goraksha-Hicks, P., et al. (2015). MYC disrupts the circadian clock and metabolism in cancer cells. Cell Metab. 22, 1009-1019. DOI |
28 | Bailey, A.M., Zhan, L., Maru, D., Shureiqi, I., Pickering, C.R., Kiriakova, G., Izzo, J., He, N., Wei, C., Baladandayuthapani, V., et al. (2014). FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G48-G58. DOI |
29 | Bonamy, C., Sechet, E., Amiot, A., Alam, A., Mourez, M., Fraisse, L., Sansonetti, P.J., and Sperandio, B. (2018). Expression of the human antimicrobial peptide beta-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells. Sci. Rep. 8, 18043. DOI |
30 | Cao, Z., Fan-Minogue, H., Bellovin, D.I., Yevtodiyenko, A., Arzeno, J., Yang, Q., Gambhir, S.S., and Felsher, D.W. (2011). MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 71, 2286-2297. DOI |
31 | Chen, H., Liu, H., and Qing, G. (2018). Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 3, 5. DOI |
32 | Conacci-Sorrell, M., McFerrin, L., and Eisenman, R.N. (2014). An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med. 4, a014357. DOI |
33 | Degirolamo, C., Modica, S., Palasciano, G., and Moschetta, A. (2011). Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol. Med. 17, 564-572. DOI |
34 | Date, Y. and Ito, K. (2020). Oncogenic RUNX3: a link between p53 deficiency and MYC dysregulation. Mol. Cells 43, 176-181. DOI |
35 | de Aguiar Vallim, T.Q., Tarling, E.J., and Edwards, P.A. (2013). Pleiotropic roles of bile acids in metabolism. Cell Metab. 17, 657-669. DOI |
36 | DeBerardinis, R.J. and Chandel, N.S. (2016). Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200. DOI |
37 | Frenzel, A., Zirath, H., Vita, M., Albihn, A., and Henriksson, M.A. (2011). Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. PLoS One 6, e27988. DOI |
38 | Fu, T., Coulter, S., Yoshihara, E., Oh, T.G., Fang, S., Cayabyab, F., Zhu, Q., Zhang, T., Leblanc, M., Liu, S., et al. (2019). FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098-1112.e18. DOI |
39 | Gomez-Ospina, N., Potter, C.J., Xiao, R., Manickam, K., Kim, M.S., Kim, K.H., Shneider, B.L., Picarsic, J.L., Jacobson, T.A., Zhang, J., et al. (2016). Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat. Commun. 7, 10713. DOI |
40 | Garcia-Gutierrez, L., Delgado, M.D., and Leon, J. (2019). MYC oncogene contributions to release of cell cycle brakes. Genes (Basel) 10, 244. DOI |
41 | Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015). The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350-1356. DOI |
42 | Houlston, R.S. (2001). What we could do now: molecular pathology of colorectal cancer. Mol. Pathol. 54, 206-214. DOI |